How to cite: Koo, Philip J. “Clinical Update on PSMA Diagnostics and Therapies.” March 10, 2023. Accessed Jul 2024. https://grandroundsinurology.com/clinical-update-on-psma-diagnostics-and-therapies/
Clinical Update on PSMA Diagnostics and Therapies – Summary
Philip J. Koo, MD, discusses the current status of PSMA PET and its role in the diagnosis, treatment, and management of prostate cancer. Dr. Koo highlights the uses of PSMA PET in patients with initial diagnosis, biochemical recurrence, and oligometastatic disease, and the variety of radiopharmaceuticals available for theranostic treatment of patients.
Dr. Koo emphasizes the evolving landscape of prostate cancer staging, with PSMA PET only being appropriate to use at certain stages. Dr. Koo concludes that PSMA PET, while not yet ready for “Prime Time,” is a powerful tool in prostate cancer management, poised to shape the future of diagnosis and patient care.
About the 30th Annual Perspectives in Urology: Point Counterpoint conference: Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, this conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking.
ABOUT THE AUTHOR
Phillip J. Koo, MD, is the Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Phoenix, Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine in Aurora, Colorado. Dr. Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian and his radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System in Philadelphia, Pennsylvania. He completed his fellowship at the Harvard Medical School Joint Program in Nuclear Medicine in Boston, Massachusetts. Dr. Koo is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine(ABNM). His academic interests have focused on PET imaging in prostate cancer, response to novel therapies using PET, and data-driven motion correction. He has lectured nationally and internationally on topics related to imaging and radiopharmaceutical based therapies in prostate cancer. In 2022, Dr. Koo was the recipient of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Presidential Distinguished Service Award.
